The latest people and business news from the past month, all in one place.
MMS Holdings announced the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors. Dr. Breitfeld is currently the chief medical officer for Allterum Therapeutics. Dr. Zeiher has also been the chief medical officer for Astellas Pharma for the past 12 years.
Catawba Research announced the hiring of Andy Silverman, PhD, as chief operating officer. Previously, Silverman worked as EVP, Global Operations for Syneos Health.
Greenphire announced the appointment of Steve Geffon to be its new chief commercial officer. Prior to joining Greenphire, Geffon spent three years in the same role at Science 37.
CluePoints revealed the hiring of Amit Patel as its new CFO. Patel joins CluePoints after serving in the same role at Siteimprove.
Innovative Trials appointed Eloise Moffett as its first commercial vice president. Before joining Innovative Trials, Moffet spent over two years as the senior director of business development for mdgroup.
EmVenio Research announced the appointment of Mark Mackenzie, MD, as chief medical officer. Previously, Mackenzie served as the vice president of clinical affairs at M-3 Wake Research.
COTA Inc. announced the hiring of Sandy Leonard as its chief commercial officer. Concurrently, Leonard is the founder of DAISE Consulting LLC.
TOTAL Diversity Clinical Management introduced three new executives to its staff including Gabrielle DeBoer as VP, business development; Jeremy Mitchell as director, business development; and Crystal Thigpen as marketing and communications director.
Cluepoints has been shortlisted for the 2023 Citeline Awards in the Best Use of Artificial Intelligence in Clinical Trials category.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.